Development and validation of a short version of the Seattle angina questionnaire.
Development and validation of a short version of the Seattle angina questionnaire.
复制标题
DOI：
10.1161/circoutcomes.114.000967
复制
发表时间：
2014-09
期刊：
影响因子：
--
通讯作者：
Spertus JA
中科院分区：
文献类型：
--
作者：
Chan PS;Jones PG;Arnold SA;Spertus JA
临床试验和国家绩效衡量标准越来越多地要求报告患者对其健康状况的看法：他们的症状、功能和生活质量。虽然西雅图心绞痛问卷（SAQ）是一种经验证的冠状动脉疾病（CAD）疾病特异性健康状态工具，具有较高的重测可靠性、预测能力和反应性，但其在常规临床实践中的使用受到限制，部分原因是其长度（19项）。使用来自5个多中心登记研究的10，408例CAD患者的数据，我们推导并验证了SAQ的缩短版本（SAQ-7），用于表现为稳定性CAD、接受经皮冠状动脉介入治疗（PCI）和急性心肌梗死（AMI）后的患者。我们研究了心理测量学性质的SAQ-7，与完整的SAQ。从生理限制、心绞痛频率和生活质量领域中确定了SAQ-7的7个项目，与每个原始SAQ领域具有高水平的一致性（0.88-1.00）。SAQ-7表现出良好的结构效度（与加拿大心血管学会心绞痛分类相比），稳定型CAD患者和接受PCI患者的相关性分别为0.62和0.38。它在稳定型CAD患者中具有高度可重复性（类内相关性≥0.78），在PCI后患者中表现出极好的反应性（每个SAQ域≥18分）。最后，SAQ-7可预测1年死亡率和再入院率。为了增加测量CAD患者患者报告结局的可行性，我们开发并验证了用于临床试验和常规护理的缩短的7项SAQ工具。
Clinical trials and national performance measures increasingly mandate reporting patients’ perspectives of their health status: their symptoms, function and quality of life. While the Seattle Angina Questionnaire (SAQ) is a validated disease-specific health status instrument for coronary artery disease (CAD) with high test-retest reliability, predictive power, and responsiveness, its use in routine clinical practice has been limited, in part, by its length (19 items). Using data from 10,408 patients with CAD from 5 multi-center registries, we derived and validated a shortened version of the SAQ (SAQ-7) among patients presenting with stable CAD, undergoing percutaneous coronary intervention (PCI), and after acute myocardial infarction (AMI). We examined the psychometric properties of the SAQ-7, as compared with the full SAQ. Seven items from the Physical Limitations, Angina Frequency, and Quality of Life domains were identified for the SAQ-7, with high levels of concordance (0.88–1.00) with each original SAQ domain. The SAQ-7 demonstrated good construct validity (compared with Canadian Cardiovascular Society class for angina), with an correlation of 0.62 and 0.38 for patients with stable CAD and undergoing PCI, respectively. It was highly reproducible in patients with stable CAD (intra-class correlation of ≥0.78) and exhibited excellent responsiveness in patients after PCI (≥18 points in each SAQ domain). Finally, the SAQ-7 was predictive of 1-year mortality and readmission. To increase the feasibility of measuring patient-reported outcomes in patients with CAD, we developed and validated a shortened 7-item SAQ instrument for use in clinical trials and routine care.